Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00068952
Status:
COMPLETED
Last Update Posted:
2008-04-01
First Post:
2003-09-12
Brief Title:
Study of IV Edotecarin Vs Temozolomide or Carmustine BCNU or Lomustine CCNU in Patients With Glioblastoma Multiforme
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase III Randomized Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine BCNU Or Lomustine CCNU In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based NEO Adjuvant Chemotherapy
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme GBM who have progression or first recurrence following initial treatment with surgery radiation and chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A5921009 | None | None | None |